GSK has received FDA approval for a hepatitis B drug that achieves functional cures in a significantly larger patient population than previous treatment options. The approval represents a clinical advance in hepatitis B management.
The drug's expanded functional cure rate addresses a significant unmet medical need in hepatitis B treatment and represents a material product approval for GSK.
The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.
Recent SEC-reported share and derivative transactions in GSK plc.
0 discretionary purchases · 0 discretionary sales
Confidence: Low
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| 10% OwnerGSK plc | Informative buy | Ordinary SharesOpen-market or private transaction (P) | 1,470,000 | $19.00 | $27,930,000 | Dec 11, 2025 |
As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 16.14%
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Fmr Llc | Sell | -2,700,005 (-3.99%) | 64,961,641 | $3,289,008 | 6/30/2026 |
| Dodge & Cox | Sell | -10,465,460 (-17.84%) | 48,197,514 | $2,440,240 | 6/30/2026 |
| Fisher Asset Management, Llc | Buy | 1,200,429 (3.477%) | 35,722,792 | $1,808,645 | 6/30/2026 |
| Primecap Management Co/Ca/ | Sell | -22,470 (-0.089%) | 25,182,068 | $1,274,968 | 6/30/2026 |
| Wellington Management Group Llp | Sell | -321,364 (-2.743%) | 11,396,249 | $576,992 | 6/30/2026 |
| Jtc Employer Solutions Trustee Ltd | Sell | -449,402 (-4.97%) | 8,592,987 | $435,063 | 6/30/2026 |
| Morgan Stanley | Sell | -3,373,089 (-30.579%) | 7,657,562 | $387,702 | 6/30/2026 |
| Royal Bank Of Canada | Buy | 82,142 (1.094%) | 7,588,928 | $384,227 | 6/30/2026 |
| Price T Rowe Associates Inc /Md/ | Sell | -399,191 (-5.451%) | 6,923,642 | $350,544 | 6/30/2026 |
| Acadian Asset Management Llc | Sell | -5,136,651 (-43.542%) | 6,660,434 | $337,218 | 6/30/2026 |
| Goldman Sachs Group Inc | Sell | -3,217,672 (-33.555%) | 6,371,442 | $322,586 | 6/30/2026 |
| State Street Corp | Sell | -39,371 (-0.656%) | 5,959,115 | $301,710 | 6/30/2026 |
Source: Nasdaq
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Sep 30, 2026 | 14,797,116 | 3,575,768 | +0.99% | 4.14 |
| Sep 15, 2026 | 14,652,083 | 2,658,073 | +8.16% | 5.51 |
| Aug 31, 2026 | 13,546,612 | 2,831,355 | -8.33% | 4.78 |
| Aug 14, 2026 | 14,778,190 | 3,317,155 | +1.80% | 4.46 |
| Jul 31, 2026 | 14,516,962 | 5,678,730 | +5.50% | 2.56 |
| Jul 15, 2026 | 13,759,806 | 3,093,122 | +7.88% | 4.45 |
| Jun 30, 2026 | 12,755,267 | 3,847,846 | +51.88% | 3.31 |
| Jun 15, 2026 | 8,398,074 | 4,276,007 | -14.03% | 1.96 |
Source: FINRA Consolidated Short Interest
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 28, 2026 | 1.36 | 1.27 | +7.09% |
| Mar 2026 | Apr 29, 2026 | 1.24 | 1.17 | +5.98% |
| Dec 2025 | Feb 4, 2026 | 0.68 | 0.64 | +6.25% |
| Sep 2025 | Oct 29, 2025 | 1.48 | 1.26 | +17.46% |
Source: Nasdaq
No published comments yet.
